| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Neuroendocrine Laboratory, Division of Endocrinology of the Department of Medicine, Mount Sinai School of Medicine of the City University of New York
L-dopa was administered to 8 patients with Cushing's disease and the resultant response of plasma growth hormone (GH) and cortisol levels was evaluated. Cushing's disease in all patients was secondary to ACTH dependent bilateral adrenal hyperplasia. Four patients had clinically active disease, the four others were in clinical remission. Seven of these subjects failed to demonstrate any elevation in plasma growth hormone levels following L-dopa administration, which is a potent stimulus to growth hormone release in normal subjects. None of the patients showed any change in plasma cortisol levels following administration of L-dopa. These patients also manifested absent growth hormone responsiveness to insulin hypoglycemia, pitressin, and PiromenTM administration. Two of these patients received therapeutic doses of L-dopa for a 5- or 10-week period, in view of reported animal findings postulating a lack of central adrenergic inhibition in Cushing's disease. Neither patient showed any amelioration of the clinical or laboratory parameters of their disease.
1 Supported by Grants NB-02893 of the U.S. Public Health Service and U.S. Public Health Service Grant FR-71 from the Division of Research Facilities and Grants, and in part by a Grant from Hoffman La Roche.
Received July 12, 1972.
This article has been cited by other articles:
![]() |
N. J. Hopwood and F. M. Kenny Incidence of Nelson's Syndrome After Adrenalectomy for Cushing's Disease in Children: Results of a Nationwide Survey Arch Pediatr Adolesc Med, December 1, 1977; 131(12): 1353 - 1356. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |